Community-Acquired Pneumonia in Children: Myths and Facts

Abstract

Community-acquired pneumonia (CAP) is the leading cause of death in children < 5 years of age worldwide. It is also one of the most frequent infectious diseases in children, leading to large antibiotic use and hospitalization even in the industrialized countries. However, the optimal management of CAP in children is still not well defined. Currently, respiratory viruses are considered the most frequent etiologic agents, but detection of viruses in the upper respiratory tract does not guarantee causation of pneumonia, nor precludes the presence of a bacterial pathogen. In both the upper and lower respiratory tract, respiratory viruses and pathogenic bacteria interact. Emerging evidence indicates that dual viral–bacterial infections function synergistically in many cases and together likely enhance the severity of CAP. Therefore, new and advanced technologies capable of sensitively and specifically discriminating viral, bacterial, and viral–bacterial coinfections are needed. Instead of focusing on the pathogen, analysis of host immune transcriptome profiles from children with CAP can potentially offer diagnostic signatures, help to assess disease severity, and eventually, prognostic indicators. An optimized management strategy by using molecular pathogen testing and transcriptome profiling will facilitate prompt, more appropriate, and targeted therapies, which in turn will lead to improved clinical outcomes in children with CAP.

Keywords

community-acquired pneumonia - children - transcriptional profiles - biomarkers

• References

• 1 Liu L, Oza S, Hogan D. , et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet 2016; 388 (10063): 3027-3035
• 2 Jain S, Williams DJ, Arnold SR. , et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 2015; 372 (09) 835-845
• 3 O'Brien KL, Baggett HC, Brooks WA. , et al. Introduction to the epidemiologic considerations, analytic methods, and foundational results from the pneumonia etiology research for child health study. Clin Infect Dis 2017; 64 (Suppl. 03) S179-S184
• 4 Nolan VG, Arnold SR, Bramley AM. , et al. Etiology and impact of coinfections in children hospitalized with community-acquired pneumonia. J Infect Dis 2018; 218 (02) 179-188
• 5 Techasaensiri B, Techasaensiri C, Mejías A, McCracken Jr GH, Ramilo O. Viral coinfections in children with invasive pneumococcal disease. Pediatr Infect Dis J 2010; 29 (06) 519-523
• 6 O'Brien KL, Walters MI, Sellman J. , et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin Infect Dis 2000; 30 (05) 784-789
• 7 Jordan-Villegas A, Chang ML, Khokhar S. , et al. Respiratory Syncytial Virus (RSV) Infection Predisposes Mice to Severe Pneumococcal Disease and Bacteremia. Infectious Diseases Society of America 48th Annual Meeting; October 21–24 2010 . Vancouver, British Columbia, Canada
• 8 Diaz A, Garcia-Maurino C, Naples J. , et al. Nasopharyngeal bacterial detection in children with RSV infection: impact on clinical outcomes. IDWeek; October 3–7 2018. San Francisco, CA
• 9 Bradley JS, Byington CL, Shah SS. , et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53 (07) e25-e76
• 10 Virkki R, Juven T, Rikalainen H, Svedström E, Mertsola J, Ruuskanen O. Differentiation of bacterial and viral pneumonia in children. Thorax 2002; 57 (05) 438-441
• 11 Spuesens EB, Fraaij PL, Visser EG. , et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med 2013; 10 (05) e1001444
• 12 Self WH, Williams DJ, Zhu Y. , et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis 2016; 213 (04) 584-591
• 13 Marzec S, Ambroggio L, Desai A. , et al for the Children's Hospital Initiative for Research in Pneumonia (CHIRP). Impact of viral testing on duration of antibiotic therapy in children hospitalized with community acquired pneumonia (CAP) in a multicenter study. 2018 Pediatric Academic Societies Annual Meeting; May 5–8 2018. Toronto, Canada.
• 14 Ramilo O, Mejías A. Shifting the paradigm: host gene signatures for diagnosis of infectious diseases. Cell Host Microbe 2009; 6 (03) 199-200
• 15 Suarez NM, Bunsow E, Falsey AR, Walsh EE, Mejias A, Ramilo O. Superiority of transcriptional profiling over procalcitonin for distinguishing bacterial from viral lower respiratory tract infections in hospitalized adults. J Infect Dis 2015; 212 (02) 213-222
• 16 Wallihan RG, Suárez NM, Cohen DM. , et al. Molecular distance to health transcriptional score and disease severity in children hospitalized with community-acquired pneumonia. Front Cell Infect Microbiol 2018; 8: 382 . Doi: 10.3389/fcimb.2018.00382
• 17 Madhi SA, Klugman KP. ; Vaccine Trialist Group. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10 (08) 811-813